Page 68 - 《中国药房》2025年22期

[ 8 ] 罗琼，胡明. 专项集采后德谷门冬双胰岛素对比甘精胰 study in China[J]. Cardiovasc Diabetol，2020，19（1）：108.
岛素U300的长期成本-效果分析[J]. 药品评价，2022，19 [23] HE C L，WANG W，CHEN Q，et al. Factors associated
（7）：385-391. with stroke among patients with type 2 diabetes mellitus
[ 9 ] GUO L X，CHEN L M，ZHAO F，et al. Improved glycae‐ in China：a propensity score matched study[J]. Acta Diabe‐
mic control in people with type 2 diabetes initiating or tol，2021，58（11）：1513-1523.
switching to IDegAsp in a real-world setting in China[J]. [24] 吴晶，贺小宁，刘艳辉. 中国2型糖尿病患者应用门冬胰
Diabetes Obes Metab，2025，27（3）：1388-1396. 岛素 30 与甘精胰岛素的成本-效果分析[J]. 中国药学杂
[10] MCCRIMMON R J，PALMER K，ALSALEH A J O，et al. 志，2016，51（3）：242-247.
Cost-effectiveness of iGlarLixi versus premix BIAsp 30 in [25] JI L N，LU J M，WENG J P，et al. China type 2 diabetes
patients with type 2 diabetes suboptimally controlled by treatment status survey of treatment pattern of oral drugs
basal insulin in the UK[J]. Diabetes Ther，2022，13（6）： users[J]. J Diabetes，2015，7（2）：166-173.
1203-1214. [26] HU Y，CHEN X W，ZOU H M，et al. Long-term clinical
[11] 国家卫生健康委员会 . 2023 年我国卫生健康事业发展 and economic effects of switching to once-weekly sema‐
统 计 公 报 [EB/OL]. （2024-08-29）[2025-06-22]. https：// glutide from other GLP-1 RAs among patients with type 2
www.gov.cn/lianbo/bumen/202408/content_6971241.htm. diabetes in China：a modeling projection study[J]. Adv
[12] 刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国 Ther，2025，42（2）：904-917.
市场出版社，2020：27-28，45-47. [27] RODBARD H W，CARIOU B，PIEBER T R，et al. Treat‐
[13] 国家统计局 . 人均国内生产总值[EB/QL]. [2025-02-28]. ment intensification with an insulin degludec（IDeg）/insu‐
https：//data.stats.gov.cn/easyquery.htm?cn＝C01. lin aspart（IAsp）co-formulation twice daily compared
[14] QUAN J C，NG C S，KWOK H H Y，et al. Development with basal IDeg and prandial IAsp in type 2 diabetes：a
and validation of the CHIME simulation model to assess randomized，controlled phase Ⅲ trial[J]. Diabetes Obes
lifetime health outcomes of prediabetes and type 2 diabe‐ Metab，2016，18（3）：274-280.
tes in Chinese populations：a modeling study[J]. PLoS [28] DUAN X T，LI Y G，LIU Q J，et al. Epidemiological cha-
Med，2021，18（6）：e1003692. racteristics，medical costs and healthcare resource utiliza‐
[15] WANG L M，GAO P，ZHANG M，et al. Prevalence and tion of diabetes-related complications among Chinese pa‐
ethnic pattern of diabetes and prediabetes in China in 2013 tients with type 2 diabetes mellitus[J]. Expert Rev Pharma‐
[J]. JAMA，2017，317（24）：2515-2523. coecon Outcomes Res，2020，20（5）：513-521.
[16] XUE M Y，SU Y X，FENG Z W，et al. A nomogram [29] RAMOS M，MEN P，WANG X，et al. Cost-effectiveness
model for screening the risk of diabetes in a large-scale of empagliflozin in patients with type 2 diabetes and estab‐
Chinese population：an observational study from 345 718 lished cardiovascular disease in China[J]. Cost Eff Resour
participants[J]. Sci Rep，2020，10（1）：11600. Alloc，2021，19（1）：46.
[17] FOLSOM A R，CHAMBLESS L E，DUNCAN B B，et al. [30] LI C Y，ZHOU H J，WANG P. Health utility of type 2 dia‐
Prediction of coronary heart disease in middle-aged adults betes patients using basal insulin in China：results from
with diabetes[J]. Diabetes Care，2003，26（10）：2777-2784. the BEYOND Ⅱ study[J]. Acta Diabetol，2021，58（3）：
[18] AN L W，WANG Y L，CAO C X，et al. Screening cardio‐ 329-339.
vascular risk factors of diabetes patients in the primary [31] BAGUST A，BEALE S. Modelling EuroQol health-
diabetes clinics[J]. Medicine（Baltimore），2021，100（30）： related utility values for diabetic complications from
e26722. CODE-2 data[J]. Health Econ，2005，14（3）：217-230.
[19] CAI X L，HU D Y，PAN C Y，et al. Evaluation of effec‐ [32] BEAUDET A，CLEGG J，THURESSON P O，et al. Re‐
tiveness of treatment paradigm for newly diagnosed type 2 view of utility values for economic modeling in type 2 dia‐
diabetes patients in China：a nationwide prospective cohort betes[J]. Value Health，2014，17（4）：462-470.
study[J]. J Diabetes Investig，2020，11（1）：151-161. [33] PAN C W，WANG S，WANG P，et al. Diabetic retinopa‐
[20] 中国疾病预防控制中心 . 2015 中国成人烟草调查报告 thy and health-related quality of life among Chinese with
[EB/OL]. （2015-12-23）[2025-06-22]. https：//cmsfiles. known type 2 diabetes mellitus[J]. Qual Life Res，2018，27
zhongkefu.com.cn/yankong/UploadFiles/2016-03/318/ （8）：2087-2093.
201603231215175-500.pdf. [34] MARRETT E，RADICAN L，DAVIES M J，et al. Assess‐
[21] World Health Organization. Global status report on alco‐ ment of severity and frequency of self-reported hypoglyce‐
hol and health and treatment of substance use disorders mia on quality of life in patients with type 2 diabetes
[EB/OL]. [2024-06-25]. https：//www.who.int/publications/ treated with oral antihyperglycemic agents：a survey study
i/item/9789240096745. [J]. BMC Res Notes，2011，4：251.
[22] ZHAO Q，ZHANG T Y，CHENG Y J，et al. Impacts of [35] 田磊，管欣，马爱霞. 随机对照试验研究与观察性研究的
triglyceride-glucose index on prognosis of patients with 系统比较[J]. 中国药房，2018，29（4）：493-496.
type 2 diabetes mellitus and non-ST-segment elevation acute （收稿日期：2025-07-22 修回日期：2025-10-28）
coronary syndrome：results from an observational cohort （编辑：孙 冰）

· 2814 · China Pharmacy 2025 Vol. 36 No. 22 中国药房 2025年第36卷第22期